Preventing Esophageal Cancer Recurrence: Michelle's Immunotherapy Story

0 Views
administrator
administrator
07/03/23

With a high risk of recurrence, Michelle wanted to do everything she could to stop her esophageal cancer from coming back and enrolled in an immunotherapy clinical trial.

Originally diagnosed in July 2016, her treatment plan progressed very quickly, including chemotherapy, radiation therapy, and surgery. Michelle’s family and coworkers helped support her throughout treatment. Declared cancer-free by the end of December 2016, she considered her next steps to stay cancer-free. In February 2017, Michelle met with Dr. Deirdre Cohen at NYU Langone Health, who recommended Michelle enroll in a clinical trial of nivolumab (Opdivo®). Now, Michelle can plan new adventures with her husband and daughter. https://www.cancerresearch.org/patients

This video is part of the 7th Annual Cancer Immunotherapy Month™ in June 2019, hosted by the Cancer Research Institute. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. https://www.cancerresearch.org..../join-the-cause/canc #Immune2Cancer

Immunotherapy patient stories are part of Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org

Sync ID: MB015CTDR8EVP7E

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next